V-A ECMO AUTO Mode Registry
Abiomed Impella V-A ECMO AUTO Mode - Observational Study
1 other identifier
observational
46
1 country
6
Brief Summary
Abiomed Impella V-A ECMO AUTO Mode - Observational Study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2023
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2023
CompletedFirst Posted
Study publicly available on registry
March 8, 2023
CompletedStudy Start
First participant enrolled
October 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 3, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 3, 2025
CompletedJuly 3, 2025
July 1, 2025
1.6 years
February 22, 2023
July 2, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Gather clinical event data
Collection of clinical events to serve as a database for an in-silico post-hoc analysis of the V-A ECMO AUTO Mode algorithm
Until one of the devices is permanently weaned, on average 5 days
Usability assessment
Confirmation of usability and ease of use by collection of user data and operational console data
Until study completion, an average of 1 year
Interventions
The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings ("events") has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software.
Eligibility Criteria
Patients treated with concomitant VA ECMO and Impella CP® heart pump (ECpella) due to severe acute heart failure by any cause (e.g. cardiogenic shock in acute myocardial infarction, cardiac arrest, myocarditis).
You may qualify if:
- Patients with ongoing or planned ECpella therapy
You may not qualify if:
- Age \< 18 years
- Treatment with other than VA ECMO setup
- Treatment with Impella CP® heart pump only
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Abiomed Inc.lead
Study Sites (6)
Uniklinik RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
HDZ NRW
Bad Oeynhausen, North Rhine-Westphalia, 32545, Germany
Herzzentrum Dresden GmbH
Dresden, Saxony, 01307, Germany
Universitäres Herz- und Gefäßzentrum Hamburg
Hamburg, 20251, Germany
UKGM Universtitätsklinikum Marburg
Marburg, Germany
Krankenhaus der Barmherzigen Brüder - Herzzentrum Trier
Trier, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alexander Kersten, MD
Uniklinik RWTH Aachen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2023
First Posted
March 8, 2023
Study Start
October 11, 2023
Primary Completion
June 3, 2025
Study Completion
June 3, 2025
Last Updated
July 3, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share